A novel and highly potent class of drugs known as antibody-drug conjugates (ADCs), utilises molecular chemistry to combine potent small molecules with mAbs that can combine the advantages of both modalities. TIA’s Biologics nodes have extensive ADC experience and in generating effective strategies around the manufacture, chemical linker design, purification, and characterisation of similar radio-labelled or high-potency bioconjugate molecules and diagnostics.